Choosing the Right Fluorescent Protein

In 1994 the green fluorescent protein cloned from Aequorea victoria became the first in a long line of genetically encoded labels. Since that time, the fluorescent protein palette has expanded to cover the entire visual spectrum. With so many color variations and options, which fluorescent protein (FP) is best for your research? Three key factors are among the most important to consider: brightness, photostability, and aggregation.

Brightness is the most obvious factor that most researchers consider when choosing an FP. In general, the brighter the FP, the better it will perform under almost all experimental conditions. When evaluating an FP’s brightness, make sure to look at the critical optical parameters — extinction coefficient and quantum yield. The product of these two values for different FPs can be used to directly compare their brightness. Brighter FPs will have lower detection limits (i.e. the concentration at which the FP becomes visible above autofluorescence of other cell components), and will allow imaging with lower excitation light intensity, minimizing the possibility of phototoxic effects.

Photostability has increasingly become a consideration when researchers choose fluorescent proteins. Many FPs, even if they are initially quite bright, will photobleach under continuous excitation during imaging. In order to perform long-term imaging experiments or to do quantitative analysis, an FP with high photostability should be the first choice. Unfortunately, methods for measuring and reporting photostability vary widely in the scientific literature, so be sure to understand how your FP’s photostability was measured before trying to make comparisons!

Aggregation (or oligomerization) has been one of the major issues tackled in the development of FPs. Many wild-type FPs form tetramers, which aggregate badly when expressed as fusion tags in cells. Engineered monomeric forms of many FPs are now available, and these monomeric FPs should always be used when making fusion constructs. For simple expression markers, however, oligomerization is not usually a major concern, and the brightest possible FP should be used in this case.

As with other research tools, doing your homework and reading the primary literature is always the best approach to choosing the right FP for your project!

Tags: Fluorescent proteins, FPs

Social Media for the Consumer

Business has become an ever changing, dynamic landscape where the power and information no longer lies strictly in the hands of “the right people.” In less than a decade Facebook has managed to link nearly a billion people from tech savvy teens to curious senior citizens. Similarly, Twitter sees over 340 million tweets that reaches over 500 million active users per day. Social media is a wide reaching technology with infinite possibilities that has been synthesized and is fueled by people, not corporations.

In a recent Industry report, 93% of businesses reported using social media as a marketing tool with the benefits being increased exposure and customer interaction (Stelzner, 2011). What does this study mean to consumers? Businesses are coming to you and responding to your feedback. Social media gives you, the consumer; back the power and the opportunity to benefit from your loyalty. Most businesses, from restaurants to labs, offer weekly tips or discounts on their services to the customers who “follow” or “like” them. Here at Allele Biotech, we have begun offering special weekly promotions, information about our products and interesting biotech news to our customers who either “follow” us on Twitter or “like” us on Facebook. For the entire month of August we are offering 15% off just for a “like” or “follow.” If you are one of the billion users, it doesn’t take much more than a click for instant rewards.

We recognize that the reason we create this technology and improve is because of the consumers. Allele Biotech would like to thank you for your loyalty and encourage you to remain active within our social media to push us forward and to help us continuously strive for more. With the creation and exponential popularity of social media, the power and information as become available to the most important people, the consumers.

Twitter @Allele_Biotech
Facebook http://www.facebook.com/pages/Allele-Biotechnology-and-Pharmaceuticals-Inc/78331924957

Cord Banking and iPS Cells

Umbilical Cord Banking (UCB) has been a popular discussion topic in the United States since the first Cord Bank was established in New York in 1992. Since the first cord blood transplantation in 1988, there have been over 780,000 UCB donations to private banks and 400,000 UCB donations to public blood banks worldwide. There has been such a great number of donations because UCB is full of hematopoietic progenitor cells, which makes it a more desirable solution to genetic, metabolic and immune disorders, over bone marrow and blood. Because of the nature of UCB, the recipient does not need to be an immunological match, there is a lower rate of infection and it is much easier to acquire than bone marrow, making it the ideal form of treatment for many patients and practitioners.

Over twenty years later, a new technology is emerging that could provide some clarity to the “to donate or not to donate” debate: induced pluripotent stem cells (iPSC). Derived from adult cells, iPSCs have the potential to be used like UCB or reprogrammed into specific tissue like myocytes. This potential opens up banking to countless individuals born before 1992, who never had an option to bank their UCB. With this unbounded potential, should iPSCs be banked liked UCB? Supporters argue that there has been enough evidence thus far to start a bank, however, most people seem to agree that too much is unknown about iPSCs and their use in humans. With that, most are in agreement that iPSC research is absolutely needed so banking can become a reality in the future.

For now iPSCs will remain in the testing and research phase, however, based on current research, iPSCs have the potential to enhance Cord Blood that has already been banked, perhaps providing some relief to public banks in the future (Broxmeyer, 2010). Though the potential of iPSCs is endless, more work has to be done before they are placed in humans and considered a viable banking system.

Tags: Cord Blood, ESCs, iPS, Stem Cell Banking, stem cells